Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists may exert neuroprotective effects relevant to Parkinson's disease.
- These compounds can cross the blood-brain barrier to varying extents.
- They demonstrate anti-inflammatory, antioxidant, and insulin-sensitizing actions.
- GLP-1 receptor agonists may reduce pathological protein aggregation.
- They are associated with the regulation of mitochondrial function.
- These agents could enhance autophagy, indicating their potential therapeutic role in Parkinson's disease.
Simplified